Selective DYRK1A Inhibitor for the Treatment of Type 1 Diabetes: Discovery of 6-Azaindole Derivative GNF2133-Reference-Cited by-同舟云学术

Selective DYRK1A Inhibitor for the Treatment of Type 1 Diabetes: Discovery of 6-Azaindole Derivative GNF2133

Published:2020-02-20 Issue:6 Volume:63 Page:2958-2973
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Liu Yahu A.¹^ORCID,Jin Qihui¹,Zou Yefen¹,Ding Qiang¹,Yan Shanshan¹,Wang Zhicheng¹,Hao Xueshi¹,Nguyen Bao¹,Zhang Xiaoyue¹,Pan Jianfeng¹,Mo Tingting¹,Jacobsen Kate¹,Lam Thanh¹,Wu Tom Y.-H.¹,Petrassi H. Michael¹,Bursulaya Badry¹,DiDonato Michael¹,Gordon W. Perry¹,Liu Bo¹,Baaten Janine¹,Hill Robert¹,Nguyen-Tran Vân¹,Qiu Minhua¹,Zhang You-Qing¹,Kamireddy Anwesh¹,Espinola Sheryll¹,Deaton Lisa¹,Ha Sukwon¹,Harb George¹,Jia Yong¹,Li Jing¹,Shen Weijun¹^ORCID,Schumacher Andrew M.¹,Colman Karyn¹,Glynne Richard¹,Pan Shifeng¹,McNamara Peter¹,Laffitte Bryan¹,Meeusen Shelly¹,Molteni Valentina¹^ORCID,Loren Jon¹^ORCID

Affiliation:

1. Genomics Institute of the Novartis Research Foundation (GNF), 10675 John Jay Hopkins Drive, San Diego, California 92121, United States

Funder

JDRF

Genomics Institute of the Novartis Research Foundation

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.9b01624

Reference53 articles.